Class / Patent application number | Description | Number of patent applications / Date published |
424100210 | Molecular bilayer structure (e.g., vesicle, liposome) | 64 |
20080206131 | Compositions and Method for Multimodal Imaging - Provided are signal modifying compositions for medical imaging comprising a carrier and two or more signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect to the signal modifying agents, which enables prolonged contrast imaging without significant depletion of the signal modifying agents from the carrier. The carriers of the present invention are lipid based or polymer based, the physico-chemical properties of which can be modified to entrap or chelate different signal modifying agents and mixtures thereof and to target specific organs or tumors or tissues within a mammal. | 08-28-2008 |
20080226546 | Kit for preparation of nano-targeted liposome drug in combined radionuclide therapy and chemotherapy - This invention is to manufacture a kit for preparation of nano-targeted liposome drugs in combined chemotherapy and radionuclide therapy. It is a kit consisting of three components: (1) A 10 ml vial A which contains BMEDA, gluconate acetate, SnCl | 09-18-2008 |
20080305037 | LINKERS FOR ANCHORING TARGETING LIGANDS - An improved linker which lacks chiral centers between a hydrophobic anchor for coupling to lipid-based particles and a targeting agent has suitable hydrophobic/hydrophilic properties for use in vivo. | 12-11-2008 |
20090068094 | INHIBITORS OF ENDO-EXONUCLEASE ACTIVITY FOR TREATING CANCER - The present invention relates to the treatment of cancer with compounds that inhibit the activity of endo-exonuclease. Endo-exonuclease has been shown to be necessary for the repair of damaged DNA. Compounds that inhibit the activity of endo-exonuclease have been shown to be particularly effective for treating cancer when used in combination with drugs that induce DNA breaks such as cisplatin and mitomycin C. These compounds have a synergistic effect when used in combination for inhibiting tumour growth. The invention includes pharmaceutical compositions for inhibiting tumour growth comprising a compound that inhibits endo-exonuclease activity. These pharmaceutical compositions preferably include compounds that induce DNA breaks. The invention includes methods of treating cancer with these pharmaceutical compositions and uses of these compositions to treat cancer. The preferred compounds that inhibit the activity of endo-exonuclease have low toxicity. One such compound is pentamidine. The invention also includes a method for diagnosing cancer and monitoring its progression. This aspect of the invention involves isolating serum from a patient; measuring the concentration of endo-exonuclease in said serum and determining whether said concentration is above a predetermined mean. | 03-12-2009 |
20090081121 | LIPOSOME COMPOSITIONS USEFUL FOR TUMOR IMAGING AND TREATMENT - The invention relates to liposome compositions for delivering, for example, therapeutic, diagnostic, and imaging agents to a subject. Methods for preparing and using such liposome compositions are further provided. The compositions and methods of the invention find particular use in treating, diagnosing, and imaging a tumor in a subject. | 03-26-2009 |
20090117035 | Temperature-Sensitive Liposomal Formulation - A liposome contains an active agent and has a gel-phase lipid bilayer membrane comprising phospholipid and a surface active agent. The phospholipids are the primary lipid source for the lipid bilayer membrane and the surface active agent is contained in the bilayer membrane in an amount sufficient to increase the percentage of active agent released at the phase transition temperature of the lipid bilayer, compared to that which would occur in the absence of the surface active agent. The surface active agent is present in the lipid bilayer membrane so as to not destabilize the membrane in the gel phase. | 05-07-2009 |
20090130018 | SUPRAMOLECULAR AGGREGATES CONTAINING CHELATING AGENTS AND BIOACTIVE PEPTIDES AS EFFECTIVE AND SELECTIVE DELIVERY TOOLS FOR DRUGS AND CONTRAST AGENTS IN MRI OR NUCLEAR MEDICINE - The invention relates to supramolecular aggregates obtained by coaggregation of two monomers: —a first monomer containing a paramagnetic or radioactive metal ion complexed by a chelating agent having a lipophilic moiety, —a second monomer containing a bioactive peptide linked to a lipophilic moiety through an organic spacer. The aggregates are selectively driven by the exposed bioactive peptide on a desired biological target. The aggregates (micelles, vesicles or liposomes) could entrap on their inner region or on their surface a pharmaceutical active principle (drug). The invention thus relates to target specific delivery of drugs and/or metal ions. The invention therefore provides compositions containing said aggregates for use as contrast agents, in nuclear medicine or MRI, for the selective delivery of drugs, and for simultaneous delivery of a drug and a metal ion. | 05-21-2009 |
20090136417 | GLYCEROL ESTER DERIVATIVE HAVING METAL CHELATE STRUCTURE - A compound represented by the following general formula (I): | 05-28-2009 |
20090136418 | Peptides specific for hepatocellular carcinoma cells and applications thereof - Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. Novel treatment strategies derived from increased knowledge of molecular oncology are constantly being developed to cure this disease. Here, we used phage display to identify novel peptides, including (SP94), which binds specifically to HCC cells. In vitro, the phage clone PC94 binds to HCC cell lines. In vivo, PC94 homed specifically to tumor tissues but not to normal visceral organs in SCID mice bearing human HCC xenografts. The homing ability could be competitively inhibited by synthetic peptide, SP94. PC94 localized to tumor tissues but could not be detected in SP94-competed tumor tissues or in normal organs. In addition, PC94 recognized the tumor tissue but not non-tumor tissue in surgical specimens from HCC patients, with a positive rate of 61.3% (19/31). With the conjugation of SP94 and liposomal doxorubicin, a targeted drug delivery system enhanced the therapeutic efficacy against HCC xenografts through enhanced tumor apoptosis and decreased tumor angiogenesis. Our results indicate that SP94 can improve the systemic treatment of patients with advanced HCC. | 05-28-2009 |
20090175784 | Anti-Alpha V Immunoliposome Composition, Methods, and Uses - An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent. | 07-09-2009 |
20090208409 | ENCAPSULATED NANOPARTICLES FOR COMPUTED TOMOGRAPHY IMAGING - A detection agent, including a polymerized liposome, a lectin, and an imaging agent, can be administered to an animal for the detection of polyps in the lower gastrointestinal tract. | 08-20-2009 |
20090214419 | SELF-ASSEMBLED BIODEGRADABLE POLYMERSOMES - The invention concerns a block copolymer of polyethylene oxide and polycaprolactone, the polyethylene oxide having a number average molecular weight from about 2.0 to about 3.8 kD, the block copolymer having a fraction of polyethylene oxide of from about 11.8 to 18.8 percent by weight. The invention also concerns polymersomes made from such copolymers and to methods of making the polymersomes. | 08-27-2009 |
20090232730 | METHOD OF PRODUCING IMMUNOLIPOSOMES AND COMPOSITIONS THEREOF - The invention provides a method for a multi-layered lipid particles in the form of liposomes that are coated first with a cryoprotectant followed by a targeting moiety over the coat of cryoprotectant, and a method for encapsulating drugs and agents in the multi-layered coated liposomes. In addition, ready-to-use liposome kits for coating with targeting agent of choice and for drug and/or agent encapsulation. | 09-17-2009 |
20090232731 | Cationic Liposomal Preparations for the Treatment of Rheumatoid Arthritis - The present invention refers to the use of cationic liposomal preparations for the treatment or diagnosis of rheumatoid arthritis or related disorders. | 09-17-2009 |
20100104507 | USE OF STERICALLY STABILIZED CATIONIC LIPOSOMES TO EFFICIENTLY DELIVER CPG OLIGONUCLEOTIDES IN VIVO - Sterically stabilized cationic liposomes (SSCL) encapsulating a K type oligodeoxynucleotide (ODN) including a CpG motif are disclosed. These SSCL encapuslating a K type ODN can be used to effectively deliver the ODN to a cell. A novel method is also disclosed for producing the SSCL encapsulating the K type ODN. Administration of the SSCL encapsulating a K type ODN and a chemotherapeutic agent, such as a chimeric molecule comprising a targeting molecule selected from the group consisting of an IL-13, and an anti-IL-13 receptor antibody; and an effector molecule selected from the group consisting of a | 04-29-2010 |
20100111840 | STABILIZED THERAPEUTIC AND IMAGING AGENTS - Stabilized lipid construct comprising a liposome or polymerized vesicle, a targeting entity, a therapeutic entity, and a stabilizing entity are provided, as well as methods for their preparation and use. | 05-06-2010 |
20100119444 | Tumor-Targeting Peptides and Uses Thereof - Tumor targeting peptides and uses thereof in tumor diagnosis and treatment. | 05-13-2010 |
20100178243 | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system - The present invention relates to a method of stabilizing a low molecular weight compound in a cationic liposome, wherein said compound has a low solubility in a lipid membrane and/or a low permeability across a lipid membrane. Preferrably, the compound is modified in order to increase lipid membrane solubility and/or lipid membrane permeability. After delivery of the cationic liposome to a target site, particularly a target site in an organism, the modification is reversed and the low molecular weight compound may enact its desired activity. | 07-15-2010 |
20100196265 | ANTI-EGFR FAMILY ANTIBODIES, BISPECIFIC ANTI-EGFR FAMILY ANTIBODIES AND METHODS OF USE THEREOF - Anti-EGFR family member antibodies and bispecific antibodies comprising one or more anti-EGFR family member antibodies are disclosed. These antibodies can be used to advantage to specifically target forms of cancer associated with the overexpression of members of the EGFR protein family. | 08-05-2010 |
20100226853 | Fluorine-18 derivatives of dasatinib and uses thereof - Provided herein are [ | 09-09-2010 |
20100272636 | Anti-CD74 Immunoconjugates and Methods of Use - Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions. | 10-28-2010 |
20110002844 | STABILIZATION OF MACROMOLECULAR MEMBRANES - Disclosed are stabilized polymersomes having layer structures. Such stabilized polymersomes are, in some embodiments, biocompatible, and are capable of enhanced, sustained release of agents. Also disclosed are related methods for synthesizing such stabilized polymersomes and methods for using such polymersomes for delivery of therapeutic, imaging, and various other agents. | 01-06-2011 |
20110027171 | PH SENSITIVE LIPOSOME COMPOSITION - Using liposomes to deliver bioactive agents to cancer or tumor cells and compositions of specific lipids that form liposomes to deliver a biologically active agent. | 02-03-2011 |
20110070155 | Anti-CD74 Immunoconjugates and Methods - Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugate compositions in therapeutic and/or diagnostic methods. | 03-24-2011 |
20110104052 | METHODS OF SYNTHESIS AND USE OF CHEMOSPHERES - The present invention provides, in general, compositions comprising a hydrogel and an agent, for example a therapeutic agent or an imaging agent, for locoregional delivery. In certain preferred embodiments of the invention, the hydrogel compositions are detectable by Magnetic Responance and CT Scan and are used for locoregional delivery of therapeutic agents, for example chemotherapeutic agents. The invention also features polymer matrix compositions comprising nanoparticles that can be loaded after polymerization with bioactive agents, for example a diagnostic agent or therapeutic agent. | 05-05-2011 |
20110158903 | ONE POT PROCESSES OF PREPARING MULTIFUNCTIONAL LIPOSOME DRUG FOR IMAGING, DELIVERY AND TARGETING IN CANCER DIAGNOSIS AND THERAPY - One pot process of preparing multifunctional liposome drug is provided. In this one pot process, liposome reacted with radionuclide labeled solution, chemotherapy drug, and targeted ligand at appropriate temperature. The product in this invention for preparation multifunctional liposome drugs in for imaging, delivery and targeting in cancer diagnosis and therapy has proved to be more simple, convenient, effective and easier than the prior art is. | 06-30-2011 |
20110165067 | CARBOHYDRATE FUNCTIONALIZED CATANIONIC SURFACTANT VESICLES FOR DRUG DELIVERY - Carbohydrate functionalized catanionic vesicles that include a glycoconjugate and/or peptidoconjugate for vaccination or drug delivery, methods for forming these, and methods of using these. | 07-07-2011 |
20110165068 | Liposome medicament, method of preparation and use thereof - This invention relates to a liposome medicament, and, more particularly, a liposome medicament with targeting function. The liposome medicament includes a medicament that is encapsulated in a liposome, and the medicament contains an effector molecule or an effector molecule that is combined with a first ligand, and a second ligand that is connected onto the surface of the liposome. The first ligand and/or the second ligand can specifically bind to target tissues or target cells to be treated. Preferably, the first ligand and/or the second ligands are antibodies, such as monoclonal antibodies. This invention also relates to a method of preparation of the liposome medicament and use of the medicament for treatment of diseases especially tumors. This invention further relates to a pharmaceutical composition of the liposome medicament and a pharmaceutically acceptable carrier. | 07-07-2011 |
20110165069 | METHODS FOR RADIOLABELING MACROMOLECULES - The present invention relates to a method for preparing a radiolabeled macromolecule, the method comprising contacting a macromolecule with a carbon encapsulated nanoparticle composite having a radioactive particulate core in an aqueous medium comprising a pH selected to promote short-range attractive forces between the nanoparticles and the macromolecule by attenuating repulsive electrostatic forces. | 07-07-2011 |
20110165070 | METHODS FOR RADIOLABELING SYNTHETIC POLYMERS - The present invention relates to a method for preparing a radiolabeled synthetic polymer, the method comprising contacting a synthetic polymer with a carbon encapsulated nanoparticle composite having a radioactive particulate core in an aqueous medium comprising an electrolyte concentration or pH selected to promote short-range attractive forces between the nanoparticles and the synthetic polymer by attenuating long-range electrostatic repulsive forces. | 07-07-2011 |
20110223103 | Multimodal Imaging of Atherosclerotic Plaque Targeted to LOX-1 - The present invention provides multiple modalities for detecting LOX-1. More particularly, an imaging composition is provided that allows for the in vivo imaging of atherosclerotic plaque. | 09-15-2011 |
20110268655 | ANTI-ALPHA V IMMUNOLIPOSOME COMPOSITIONS, METHODS AND USES - An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent. | 11-03-2011 |
20110274617 | Antibody-Targeted Carrier For Contrast Agents - A nanoconjugate is formed from a self-assembled unilamellar vesicle (ULV), at least one contrast agent which may be a MRI contrast agent, a radioisotope or a fluorophore, and at least one antibody, which may be an IgG or an antibody fragment such as a single-domain antibody. The nanoconjugate be targetted with the antibody to receptors specific to certain disease states, and thus be used in diagnostic and imaging methods using the properties o contrast agent. | 11-10-2011 |
20110311442 | DIRECT CELLULAR ENERGY DELIVERY SYSTEM - A lipid vesicle comprising a phospholipid which is a stable vesicle former and at least one unstable vesicle forming member, wherein the unstable vesicle forming member is selected from the group consisting of a polar lipid which is not a stable vesicle former, a PEG, a raft former and a fusion protein is provided. The vesicle can further comprise a biomolecule, such as for example ATP. Methods of using the vesicle for delivery of biomolecules are also provided. | 12-22-2011 |
20120020878 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS - The present invention comprises a method for delivering pharmaceutical and/or imaging agents within and/or through the dermal, mucosal and other cellular membranes, and across the blood-brain barrier, utilizing a fusogenic protein. The fusogenic protein is associated with a phospholipid membrane, such as a liposome. The liposome may include dioleoylphosphatidylserine, a negatively charged long-chain lipid. Alternatively, the liposome is comprised of a mixture of negatively charged long-chain lipids, neutral long-chain lipids, and neutral short-chain lipids. Preferred fusogenic proteins include saposin C and other proteins, polypeptides and peptide analogs derived from saposin C. The active agent contained within the liposome may comprise biomolecules and/or organic molecules. This technology can be used for both cosmetic and medicinal applications in which the objective is delivery of the active agent within and/or beneath biological membranes or across the blood-brain barrier and neuronal membranes. | 01-26-2012 |
20120082616 | Aptamer Conjugates for Targeting of Therapeutic and/or Diagnostic Nanocarriers - The present invention provides targeted delivery compositions and their methods of use in treating and diagnosing a disease state in a subject. | 04-05-2012 |
20120107232 | KIT FOR PREPARING A RADIOLABELED LIPOSOME AND A METHOD USING THE SAME - A kit for preparing a radiolabeled liposome is provided, the kit including a liposome suspension and a radionuclide, wherein the liposome suspension includes a conjugate with a structure of [chelator-hydrophilic polymer-lipid]. A method for preparing a radiolabeled liposome using the kit is also disclosed herein, thereby the radiolabeled liposome being produced with the conjugate connected to the surface therein. The advantages of the present disclose such as simple, convenient and without purifying for the produced radiolabeled liposome are thus achieved. Further, the produced radiolabeled liposome has a high specific activity and a high sensitivity and suits for the clinical use. | 05-03-2012 |
20120128582 | METHODS AND COMPOSITIONS OF [32P]-LABELED ADENINE NUCLEOTIDES FOR THE TREATMENT OF ATHEROSCLEROSIS, VASCULAR ARTERIAL DISEASES AND CORONARY ARTERY DISEASES - A method for the treatment of atherosclerosis. The method includes the administration of a 32P-labeled agent as a beta emitter, such as 32P-labeled ATP or other 32P-labeled adenine nucleotides, whereby the 32P-labeled agent seeks and then permeates the atherosclerotic plaque en bloc without prior degradation. The accumulation of the 32P-labeled agent in the atherosclerotic plaque is achieved at time points whereby the 32P-labeled agent is cleared from the blood. Thus, radionuclide-labeled adenine nucleotides accumulate with high specificity in atherosclerotic lesions and in the heart. The beta particles (electrons) emitted by the 32P-label have a maximal path distance of about 0.5 cm and their energy preferentially destroy cells present in the atherosclerotic plaque without affecting vessel integrity or inducing arterial thrombosis. | 05-24-2012 |
20120164065 | METHOD AND COMPOSITION FOR TREATING CANCER - A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species. | 06-28-2012 |
20120282172 | TARGETED DELIVERY TO HUMAN DISEASES AND DISORDERS - The present invention provides a system presenting site-specific accumulation through a ligand that specifically targets a receptor overexpressed on the surface of specific cells within a target organ, like, for example, tumor cells and/or vascular cells of tumor blood vessels. Moreover, this invention provides a method where, upon internalization of the previous-mentioned system by the target cells, triggered release at a high rate of the associated agent takes place, permitting efficient intracellular delivery and, thus, increased concentration of the transported cargo at the target site. Overall, this invention provides a method for the diagnosis, prevention and treatment of human diseases and disorders. | 11-08-2012 |
20130071321 | DELIVERY OF AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED LIPOSOMES - The invention described herein pertains to folate-receptor targeted agents comprising therapeutic agents useful for the treatment of inflammatory disease, including folate-receptor targeted liposomes (folate-targeted liposomes) containing entrapped therapeutic agents and folate-receptor targeted dendrimers conjugated to therapeutic agents (folate-targeted dendrimer conjugates), useful for the treatment of inflammatory disease, including auto-immune disease, as well as to folate-targeted liposomes containing entrapped imaging agents and dendrimer conjugates conjugated to imaging agents, for use in the diagnosis and monitoring of treatment in such disease. | 03-21-2013 |
20130142729 | Anti-CD74 Immunoconjugates and Methods of Use - Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions. | 06-06-2013 |
20130183234 | Compositions Useful for Target, Detection, Imaging and Treatment, and Methods of Production and Use Thereof - Compositions useful for target detection, imaging and treatment, as well as methods of production and use thereof, are disclosed herein. | 07-18-2013 |
20130230457 | Thermosensitive Nanoparticle Formulations and Method of Making The Same - The present invention relates to a formulation of thermosensitive liposomes, and more specifically to a formulation of liposomes comprising phospholipids and a surface active agent, wherein the liposomes support long term storage at temperatures less than or equal to about 8° C., control degradate formation to maximize product potency and release their contents at mild hyperthermic temperatures. Methods of making formulations are also described. | 09-05-2013 |
20130243688 | ANIONIC LIPIDS AND LIPID NANO-STRUCTURES AND METHODS OF PRODUCING AND USING SAME - Anionic non-phospholipids, as well as lipid nanostructures formed therefrom, are disclosed herein. Also disclosed are methods of producing and using same. | 09-19-2013 |
20130251630 | Entrapment of Radionuclides in Nanoparticle Compositions - The present invention is directed to the technical field of imaging compositions useful for diagnosing cancer and other diseases in a subject. In particular, the invention relates to a class of diagnostic compounds comprising a novel liposome composition with encapsulated metal entities such as radionuclides, for example | 09-26-2013 |
20130323165 | Magnetic Nanoplatforms for Theranostic and Multi-Modal Imaging Applications - Disclosed are nanoparticle compositions comprising paramagnetic particles, radiolabels, fluorophores, and/or positron emission tomography agents encapsulated within a biocompatible vehicle. In addition, methods of multi-modal diagnostic imaging and treating diseased tissues are disclosed, wherein the methods comprises administering a nanoparticle composition to a subject in which the nanoparticle composition comprises paramagnetic particles, radiolabels, fluorophores, and positron emission tomography agents encapsulated within a biocompatible vehicle. | 12-05-2013 |
20130330274 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING CANCER - Macrophages within the tumor microenvironment, also called tumor associated macrophages (TAMs) have been shown to play a major role in the growth and spread of many types of cancer. Cancer cells produce cytokines that cause the macrophages to differentiate into an M2 subtype. We have designed a mannosylated liposome (MAN-LIPs) and successfully showed it to accumulate in TAMs in a mouse model of pulmonary adenocarcinoma. These liposomes are loaded with | 12-12-2013 |
20140105817 | Composition and Delivery Vehicle for Active Agents and Methods Therefor - A vehicle composition in the form of a vesicular composition or a particular composition and, optionally, an active agent associated with the vesicle forming components or particles, and folate receptor alpha is used as a delivery system for the transport of components and/or active agents into the cerebrospinal fluid (CSF) and/or brain and/or central nervous system and/or spinal cord. The composition is used for treating of CSF or brain pertaining diseases, disorders or conditions, such as preventing or treating neurological or neurodegenerative diseases, disorders or conditions. | 04-17-2014 |
20140105818 | Novel Vesicles and Nanostructures from Recombinant Proteins - The present invention includes a composition comprising at least one oleosin-like protein. The present invention also includes a composition comprising a vesicle comprising at least one oleosin-like protein. | 04-17-2014 |
20140147380 | GUANYLYLCYCLASE C LIGANDS - Guanylin cyclase C compound of the inventions are disclosed. Conjugated compounds comprising guanylin cyclase C compound of the inventions conjugated to detectable or therapeutic moieties are disclosed. Methods of detecting, imaging and treating cancer and treating diarrhea are disclosed. | 05-29-2014 |
20140178296 | TUMOR-TARGETED NANODELIVERY SYSTEMS TO IMPROVE EARLY MRI DETECTION OF CANCER - The present invention is in the fields of drug delivery, cancer treatment and diagnosis and pharmaceuticals. This invention provides a method of making antibody- or antibody fragment-targeted immunoliposomes for the systemic delivery of molecules to treat and image diseases, including cancerous tumors. The invention also provides immunoliposomes and compositions, as well as methods of imaging various tissues. The liposome complexes are useful for encapsulation of imaging agents, for example, for use in magnetic resonance imaging. The specificity of the delivery system is derived from the targeting antibodies or antibody fragments. | 06-26-2014 |
20140193330 | COMPOSITIONS AND METHODS FOR MULTIMODAL IMAGING - There is provided signal modifying compositions for medical imaging comprising a carrier and signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect of the signal modifying agents that enables prolonged contrast imaging without significant depletion of the signal modifying agent from the carrier. The carriers of the present invention are lipid based or polymer based the physico-chemical properties of which can be modified to entrap or chelate different signal modifying agents and mixtures thereof and to target specific organs or tumors or tissues within a mammal. | 07-10-2014 |
20140234210 | METAL BISPHOSPHONATE NANOPARTICLES FOR ANTI-CANCER THERAPY AND IMAGING AND FOR TREATING BONE DISORDERS - Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents. | 08-21-2014 |
20140234211 | SUPRAMOLECULAR AGGREGATES CONTAINING AMPHIPHILIC MONOMERS, CHELATING AGENTS AND PEPTIDES FOR USE FOR DRUG DELIVERY AND AS CONTRAST AGENTS - Delivery systems based on liposomes functionalized with peptides and chelating agents, for therapy and imaging by selective targeting of tumour cells expressing the receptors GRP, BB1, BB2, BB3 e BB4 and any other receptor which recognizes the bombesin peptide or analogues thereof are described. In particular, the liposomes contain within them cytotoxic drugs, such as for example doxorubicin, for target-selective antitumour therapy, and, through the presence of the chelating agent, can contain radioactive or paramagnetic ions for the real time visualization of the tumour cells. The liposomes described in this invention thus act as a selective delivery system for drugs and/or contrast agents onto tumour cells expressing the receptors for the class of known peptides such as bombesin (endogenous sequence, analogous or peptidomimetic peptides, agonists or non agonists). | 08-21-2014 |
20140377169 | Automated synthesis device to produce Re-188-Liposome and method thereof - An automated synthesis device to produce Re-188-BMEDA solution including: a plurality of reagent vials, three-way solenoid valves, gel filtration columns and micro pumps, and a reaction vial, a product vial, a temporary storage vial, a filter membrane, and a waste vial, wherein the plurality of reagent vials include first reagent vial and second reagent vials being connected to the reaction vial through first micro pump, the third reagent vial and fourth reagent vial being connected to the reaction vial through second micro pump, fifth reagent vial being connected to the reaction vial through third micro pump, and sixth reagent vial being connected to the temporary storage vial through fourth micro pump, wherein the reaction vial is connected to the plurality of gel filtration columns through the micro-pump, respectively. The automated synthesis device is operable with program to upgrade yield and avoid contamination. | 12-25-2014 |
20150093328 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING - The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique. | 04-02-2015 |
20150098898 | PHARMACEUTICAL COMPOSITION, METHOD AND KIT FOR DETECTING HUMAN MELANOMA CELLS - The present disclosure is related to a pharmaceutical composition for detecting human melanoma cells, including: a liposome, a biomolecule having specificity for α | 04-09-2015 |
20150110713 | METHOD AND COMPOSITION FOR TREATING CANCER - A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species. | 04-23-2015 |
20150343100 | BIMODAL FLUOROPHORE-LABELED LIPOSOMES AND ASSOCIATED METHODS AND SYSTEMS - Described herein is a non-invasive quantitative positron emission tomography (PET) nanoreporter technology that allows personalized therapeutic outcome prediction. In a breast cancer mouse model, it was demonstrated that co-injecting Doxil and a Zirconium-89 nanoreporter ( | 12-03-2015 |
20160015839 | Rare Earth Doped Nanoparticles for Use in Hyperthermia Treatment of Cells - An approach to hyperthermia for cancer treatment based on multiphonon relaxation of optical excitation in rare-earth (particularly Dy | 01-21-2016 |
20160030600 | TARGETED DELIVERY OF NANOPARTICLES TO EPICARDIAL DERIVED CELLS (EPDC) - This invention relates to nanoparticles for use in the in vivo diagnostics of epicardial derived cells (EPDCs) to nano particles for use in the treatment of cardiac injury. The invention further relates to a method for analyzing EPDCs, to a method for labeling EPDCs, and to a method for transferring a therapeutic agent into an EPDC. | 02-04-2016 |
20160114061 | KIT FOR PREPARATION OF TARGET RADIOPHARMACEUTICALS AND METHOD OF USING IT - The invention relates to a kit for preparation of target radiopharmaceuticals, a method of using the kit to prepare target radiopharmaceuticals and use of the target radiopharmaceuticals. The target radiopharmaceuticals comprise a radio-nuclear loading on liposome and inhibit the tumor growth and metastatic progression of head and neck cancer, lung cancer and brain cancer. The radiopharmaceuticals may be used for treating the mentioned cancers. | 04-28-2016 |
20160158392 | Entrapment of Radionuclides in Nanoparticle Compositions - The present invention is directed to the technical field of imaging compositions useful for diagnosing cancer and other diseases in a subject. In particular, the invention relates to a class of diagnostic compounds comprising a novel liposome composition with encapsulated metal entities such as radionuclides, for example | 06-09-2016 |